Knight-Swift Transportation Holdings Inc. vs Moderna, Inc. — how do they compare? Knight-Swift Transportation Holdings Inc. trades at $64.47 (market cap $10.59B), while Moderna, Inc. trades at $225 (market cap $78.65B). The key difference: Moderna, Inc. is far larger — about 7.4× Knight-Swift Transportation Holdings Inc.'s market cap, and Knight-Swift Transportation Holdings Inc. pays a 1.23% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Knight-Swift Transportation Holdings Inc. for 1 Days and Moderna, Inc. for 59 Days on average.
| KNX | MRNA | |
|---|---|---|
Market Cap | $10.59B | $78.65B |
Volume | 2,972,511 | 37,373,437 |
Sector | Industrials | Health |
52-Week High | $82.45 | $225.00 |
52-Week Low | $41.68 | $22.36 |
Typical Hold Time | 1 Days | 59 Days |
Enterprise Value | $13.09B | $74.80B |
Dividend Yield | 1.23% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Moderna (MRNA) trades at $197.00, up 0.26% on the day, with technical indicators showing a bullish trend and strong momentum. The stock has rallied over 500% in 2026, driven by positive clinical updates for its cancer vaccine pipeline and inclusion in the Nasdaq-100 index effective October 9, 2026. However, fundamentals remain challenging with revenue declining from $18.9B in 2022 to $1.9B in 2025 and negative net income margins exceeding 140%.
While technical momentum and pipeline optimism support near-term upside, valuation appears stretched with P/S of 35.08 and negative profitability metrics. Key risks include execution on non-COVID products, competitive pressure, and sustainability of recent gains. Analyst consensus is cautious with only 28% buy ratings and $115.70 price target suggesting significant downside from current levels.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Knight-Swift provides truckload, less-than-truckload, logistics, and freight management services. It operates a large transportation network across North America.
Read more on KNX →Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →